Skip to content
Menu

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31

Benzinga Newsdesk 2 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $33 to $31.

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $33 to $31.

Read at benzinga.com